The switch from interferon-β to natalizumab treatment is more effective in patients with relapsing forms of multiple sclerosis when administered early during the disease course

被引：0
|
作者：
Lourbopoulos, A. [1 ]
Giantzi, V. [1 ]
Chatzikyriakou, E. [1 ]
Liaptsi, E. [1 ]
Tascos, N. [1 ]
Grigoriadis, N. [1 ]
机构：
[1] AHEPA Univ Hosp, Thessaloniki, Greece
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：217 / 218
页数：2
相关论文
共 50 条
  • [21] Changes of diffusion in normal appearing white matter during treatment with interferon-β are not associated with clinical course of multiple sclerosis
    Zacharzewska-Gondek, A.
    Pokryszko-Dragan, A.
    Gondek, T.
    Sasiadek, M.
    Bladowska, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S600 - S600
  • [22] Interferon beta-1b is effective and has a favourable safety profile in Chinese patients with relapsing forms of multiple sclerosis
    Li, Z. X.
    Lu, C. Z.
    Zhang, X. H.
    Cui, L. Y.
    Xu, X. H.
    Radue, E.
    Chu, S. G.
    Wang, L. R.
    Beckmann, K.
    Lampe, J.
    Pohl, C.
    Stemper, B.
    Sandbrink, R.
    NEUROLOGY ASIA, 2014, 19 (02) : 179 - 189
  • [23] Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
    Luca Prosperini
    Giovanna Borriello
    Laura De Giglio
    Laura Leonardi
    Valeria Barletta
    Carlo Pozzilli
    BMC Neurology, 11
  • [24] Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: The Escala Study
    Meca-Lallana, J. E.
    Balseiro, J. J.
    Lacruz, F.
    Guijarro, C.
    Sanchez, O.
    Cano, A.
    Costa-Frossard, L.
    Hernandez-Clares, R.
    Sanchez-de la Rosa, R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 315 (1-2) : 123 - 128
  • [25] Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
    Prosperini, Luca
    Borriello, Giovanna
    De Giglio, Laura
    Leonardi, Laura
    Barletta, Valeria
    Pozzilli, Carlo
    BMC NEUROLOGY, 2011, 11
  • [26] Efficacy, Safety and JC-Antibody Prevalence Following Natalizumab Treatment for 36 Month and More in Patients with Relapsing Remitting Multiple Sclerosis
    Sorgalla, Susanne
    Gerbershagen, Kathrin
    Bernsen, Sarah
    Lang, Michael
    Schmidt, Stephan
    Marziniak, Martin
    Wiendl, Heinz
    Limmroth, Volker
    NEUROLOGY, 2012, 78
  • [27] Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice
    Lanzillo, R.
    Bonavita, S.
    Quarantelli, M.
    Vacca, G.
    Lus, G.
    Amato, L.
    Carotenuto, A.
    Tedeschi, G.
    Orefice, G.
    Morra, V. Brescia
    NEUROLOGICAL SCIENCES, 2013, 34 (04) : 521 - 528
  • [28] Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice
    R. Lanzillo
    S. Bonavita
    M. Quarantelli
    G. Vacca
    G. Lus
    L. Amato
    A. Carotenuto
    G. Tedeschi
    G. Orefice
    V. Brescia Morra
    Neurological Sciences, 2013, 34 : 521 - 528
  • [29] Effect of early switch to fingolimod from other oral therapies in patients with relapsing-remitting multiple sclerosis
    Ziemssen, T.
    Silva, D.
    Medin, J.
    Cornelissen, C.
    Ringwald, K.
    Cohan, S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 404 - 405
  • [30] The effects of natalizumab and interferon beta-1a on clinical measures in patients with relapsing multiple sclerosis:: 2-year results from SENTINEL
    Rudick, RA
    Stuart, WH
    Calabresi, PA
    Confavreux, G
    Galetta, SL
    Radü, EW
    Lublin, FD
    Weinstock-Guttman, B
    Wynn, DR
    Lynn, F
    Panzara, MA
    Sandrock, AW
    MULTIPLE SCLEROSIS, 2005, 11 : S12 - S12
12345